Expression of the bcl-2 homologue bax in normal human skin, psoriasis vulgaris and non-melanoma skin cancers

European Journal of Dermatology

Volumn 8, Issue 4, 1998, Pages 256-260

  Tomková, Hana ^a   Fujimoto, Wataru ^a   Arata, Jiro ^a  

^a OKAYAMA UNIVERSITY MEDICAL SCHOOL   (Japan)

Author keywords

Apoptosis; Bax; Bcl 2 family; Skin

Indexed keywords

PROTEIN BAX; PROTEIN BCL 2;

APOPTOSIS; ARTICLE; BASAL CELL CARCINOMA; CONTROLLED STUDY; GENE EXPRESSION; HUMAN; HUMAN TISSUE; IMMUNOBLOTTING; IMMUNOREACTIVITY; KERATOACANTHOMA; PROTEIN LOCALIZATION; PSORIASIS VULGARIS; SKIN; SKIN CANCER; SQUAMOUS CELL CARCINOMA;

APOPTOSIS; BIOPSY, NEEDLE; BLOTTING, WESTERN; CARCINOMA, BASAL CELL; CARCINOMA, SQUAMOUS CELL; HUMANS; IMMUNOHISTOCHEMISTRY; PROTO-ONCOGENE PROTEINS C-BCL-2; PSORIASIS; REFERENCE VALUES; SENSITIVITY AND SPECIFICITY; SKIN; SKIN NEOPLASMS;

EID: 0031817363     PISSN: 11671122     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (44)

1. Pan H, Yin C, van Dyke T. Apoptosis and cancer mechanisms. Cancer Surveys 1997; 29: 305-27.
2. Kernohan NM, Cox LS. Regulation of apoptosis by bcl-2 and its related proteins: immunochemical challenges and therapeutic implications. J Pathol 1996; 179: 1-3.
3. Kandouz M, Gompel A, Therwath A. Bcl-2 proto-oncogene, apoptosis and oncogenesis: an overview. Int J Oncol 1996; 9: 563-6.
4. Yang E, Korsmeyer SJ. Molecular thanatopsis: a discourse on the Bcl-2 family and cell death. Blood 1996; 88: 386-401.
5. Oltvai ZN, Milliman LL, Korsmeyer SJ. Bcl-2 heterodimerizes in vivo with a conserved homolog, Bax, that accelerates programmed cell death. Cell 1993; 74: 609-19.
6. Reed JC. Mechanisms of Bcl-2 family protein function and dysfunction in health and disease. Behring Inst Mitt 1996; 97: 72-100.
7. Ito T, Deng X, Carr B, May WS. Bcl-2 phosphorylation required for anti-apoptosis function. J Biol Chem 1997; 272: 11671-3
8. Zha H, Reed JC. Heterodimerization-independent functions of cell death regulatory proteins bax and bcl-2 in yeast and mammalian cells. J Biol Chem 1997; 272: 31482-8.
9. Franke TF, Cantley LC. A bad kinase makes good. Nature 1997; 390: 116-7.
10. Beham A, Marin MC, Fernandez A, Herrmann J, Brisbay S, Tari AM, Lopez-Berestein G, Lozano G, Sarkiss M, McDonnell TJ. Bcl-2 inhibits p53 nuclear import following DNA damage. Oncogens 1997; 15: 2767-72.
11. Krajewski S, Krajewska M, Shabaik A, et al. Immunohistochemical determination of in vivo distribution of Bax, a dominant inhibitor of Bcl-2. Am J Pathol 1994; 145: 1323-36.
12. Wolter KG, Hsu YT, Smith CL, Nechushtan A, Xi XG, Youle RJ. Movement of bax from the cytosol to mitochondria during apoptosis. J Cell Biol 1997; 139: 1281-92.
13. L during apoptosis. Proc Natl Acad Sci USA 1997; 94: 3668-72.
14. Song Y, Yaar M, Gilchrest BA. Evidence that bax mediates keratinocyte differentiation and apoptosis. J Invest Dermatol 1996; 106: 875 (abstr.).
15. Sarbia M, Bittinger F, Grabellus F, et al. Expression of bax, a proapoptotic member of the bcl-2 family, in esophageal squamous cell carcinoma. Int J Cancer 1997; 73: 508-13.
16. Krajewski S, Blomqvist C, Franssila K, et al. Reduced expression of proapoptotic gene bax is associated with poor response rates to combination chemotherapy and shorter survival in women with metastatic breast adenocarcinoma. Cancer Res 1995; 55: 4471-8.
17. LeBrun DP, Warnke RA, Cleary ML. Expression of bcl-2 in fetal tissues suggests a role in morphogenesis. Am J Pathol 1993; 142: 743-53.
18. Hockenbery DM, Zutter M, Hickey W, et al. Bcl-2 is topographically restricted in tissues characterized by apoptotic cell death. Proc Natl Acad Sci USA 1991; 88: 6961-5.
19. Cerroni L, Kerl H. Aberrant bcl-2 protein expression provides a possible mechanism of neoplastic growth in cutaneous basal-cell carcinoma. J Cutan Pathol 1994; 21: 398-403.
20. Nakagawa K, Yamamura K, Maeda S, Ichihashi M. Bcl-2 expression in epidermal keratinocytic diseases. Cancer 1994; 74: 1720-4.
21. Van den Oord JJ, Vandeghinste N, De Ley M, De Wolf-Peeters C. Bcl-2 expression in human melanocytes and melanocytic tumors. Am J Pathol 1994; 145: 294-300.
22. Kanitakis J, Montazeri A, Ghohestani R, et al. Bcl-2 oncoprotein expression in benign nevi and malignant melanomas of the skin. Eur J Dermatol 1995; 5: 501-7.
23. Moll I, Gillardon F, Waltering S, et al. Differences of bcl-2 protein expression between Merkel cells and Merkel cell carcinomas. J Cutan Pathol 1996; 23: 109-17.
24. Wrone-Smith T, Johnson T, Nelson B, et al. Discordant expression of Bcl-x and Bcl-2 by keratinocytes in vitro and psoriatic keratinocytes in vivo. Am J Pathol 1995; 146: 1079-88.
25. Sermadiras S, Dumas M, Joly-Berville R, et al. Expression of bcl-2 and bax in cultured normal human keratinocytes and melanocytes: relationship to differentiation and melanogenesis. Br J Dermatol 1997; 137: 883-9.
26. Bianchi L, Farrace MG, Nini G, Piacentini M. Abnormal bcl-2 and "tissue" transglutaminase expression in psoriatic skin. J Invest Dermatol 1994; 103: 829-33.
27. Tomková H, Fujimoto W, Arata J. Expression of bcl-2 antagonist bak in inflammatory and neoplastic skin diseases. Br J Dermatol 1997; 137: 703-8.
28. Arends MJ, McGregor AH, Wyllie AH. Apoptosis is inversely related to necrosis and determines net growth in tumors bearing constitutively expressed myc, ras, and HPV oncogenes. Am J Pathol 1994; 144: 1045-57.
29. Weinstein GD, Frost P. Cell proliferation in human basal cell carcinoma. Cancer Res 1970; 30: 724-8.
30. Kerr JFR, Searle J. A suggested explanation for the paradoxically slow growth rate of basal-cell carcinoma that contain numerous mitotic figures. J Pathol 1972; 107: 41-4.
31. Mooney EE, Ruis Peris JM, O'Neill A, Sweeney EC. Apoptotic and mitotic indices in malignant melanoma and basal cell carcinoma. J Clin Pathol 1995; 48: 242-4.
32. Verhaegh MEJM, Sanders CJG, Arends JW, Neumann HAM. Expression of the apoptosis suppressing protein Bcl-2 in non-melanoma skin cancer. Br J Dermatol 1995; 132: 740-4.
33. Morales-Ducret CRJ, van de Rijn M, LeBrun DP, Smoller BR. Bcl-2 expression in primary malignancies of the skin. Arch Dermatol 1995; 131: 909-12.
34. Pietenpol JA, Papadopoulos N, Markowitz S, et al. Paradoxical inhibition of solid tumor cell growth by bcl-2. Cancer Res 1994; 54: 3714-7.
35. Middleton G, Nunez G, Davies AM. Bax promotes neuronal survival and antagonises the survival effects of neurotrophic factors. Development 1996; 122: 695-701.
36. Kiefer MC, Brauer MJ, Powers VC, et al. Modulation of apoptosis by the widely distributed Bcl-2 homologue Bak. Nature 1995; 374: 736-9.
37. Reed JC. Double identity for proteins of the Bcl-2 family. Nature 1997; 387: 773-6.
38. Sleater JP, Beers BB, Stephens CA, Hendricks JB. Keratoacanthoma: a deficient squamous cell carcinoma? Study of bcl-2 expression. J Cutan Pathol 1994; 21: 514-9.
39. Wikonkal NM, Berg RJW, van Haselen CW, et al. Bcl-2 vs p53 protein expression and apoptotic rate in human nonmelanoma skin cancers. Arch Dermatol 1997; 133: 599-602.
40. Miyashita T, Krajewski S, Krajewska M, et al. Tumor suppressor p53 is a regulator of bcl-2 and bax gene expression in vitro and in vivo. Oncogene 1994; 9: 1799-805.
41. Miyashita T, Reed JC. Tumour suppressor p53 is a direct transcriptional activator of the human bax gene. Cell 1995, 80: 293-9.
42. McGregor JM, Yu CC, Dublin EA, et al. Aberrant expression of p53 tumour-suppressor protein in non-melanoma skin cancer. Br J Dermatol 1992; 127: 463-9.
43. Borkowski A, Bennett WP, Jones RT, et al. Quantitative image analysis of p53 protein accumulation in keratoacanthomas. Am J Dermatopathol 1995; 17: 335-8.
44. Cain CT, Niemann TH, Argenyi ZB. Keratoacanthoma versus squamous cell carcinoma. An immunohistochemical reappraisal of p53 protein and proliferating cell nuclear antigen expression in keratoacanthoma-like tumors. Am J Dermatopathol 1995; 17: 324-31.